关键词:
HIV antibody positivity
Influencing factors
New type drugs
Trend
摘要:
Objective To analyze the HIV antibody positivity of new type drug users in drug abuse monitoring sites in Zhejiang Province from 2017 to 2023 and its influencing factors. Methods From 2017 to 2023, a continuous cross-sectional survey was carried out in HIV monitoring posts among new type drug users in Zhejiang Province,the sample size was 400 people per site of 9 drug abuse surveillance sites in 7 cities. Questionnaires were conducted to investigate their social demographic information, related behavioral information, AIDS awareness, and acceptance of intervention measures, and blood was collected for HIV and syphilis antibody detection, with new type drugs users in the monitoring population as the research object. SPSS 22.0 software was used for statistical analysis. Results A total of 13 955 new drug users were surveyed, and the number of new drug users was 2 518, 2 292, 2 526, 2 119, 2 161, 1 064 and 1 275 from 2017 to 2023, respectively, the HIV antibody positive rate of new type drugs users was 0.44%, 1.09%, 2.06%, 1.09%, 1.39%, 1.50%, 2.90%, respectively, and the HIV antibody positive standardized rate showed an increasing trend (all P<0.001). The results of multivariate logistic regression analysis showed that marital status: unmarried/divorced/widowed (aOR=3.92, 95%CI: 2.46-6.25), provincial household registration (aOR=3.54, 95%CI: 2.34-5.35), high school education or above (aOR=5.42, 95%CI: 3.68-7.98), sexual activity within the last 1 year after drug use (aOR=1.84, 95%CI: 1.19-2.84), and knowledge that the use of new drugs increases the risk of HIV infection (aOR=2.27, 95%CI: 1.17-4.39) were associated with increased HIV antibody favorable rates among new type drugs users. Conclusions During 2017-2023, the HIV antibody-positive rate of new type drug users in Zhejiang Province showed an upward trend. It is necessary to strengthen the monitoring and intervention of this population. © 2025 Chinese Medical Journals Publishing House ***. All rights reserved.